August 25, 2015 9:28am
Although the scleroderma patient population tends to be thin, the fat harvest procedure and injection can be performed in a straightforward fashion and was well tolerated. CYTX is so cheap - a BUY ensues however, the short and near-term future are still lean. BARDA will be the key but, when?
Members only. Please login.
35 companies, 1 interpreter!
Insight, foresight and recommendation
2 hours 52 min ago
RegMed Investors (RMi) Closing Bell: I told you so
11 hours 40 min ago
RegMed Investors’ (RMi) pre-open: It’s “make” a buck day!
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2024 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.